Enlivex Secures Australian Patent for Allocetra™ in Osteoarthritis Treatment Through 2040

Enlivex Ltd. (Nasdaq: ENLV), an Israeli quality longevity company, announced on June 15, 2026, the issuance of Australian patent number 2020340629 titled "THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS." This patent provides Enlivex with intellectual property protection in Australia through at least 2040, covering methods of using Allocetra™ to treat patients with osteoarthritis.

The patent issuance marks a significant expansion of Enlivex’s global intellectual property portfolio for Allocetra™, an advanced clinical-stage immunotherapy designed to target inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis.

Enlivex recently reported dosing the first patient at a U.S. clinical site in its Phase 2b clinical trial evaluating Allocetra™ for moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). This Phase 2b trial follows positive topline data at three and six months from the earlier Phase I/II double-blind, randomized, placebo-controlled study (ENX-CL-05-001), which assessed Allocetra™ in patients with moderate-to-severe knee OA.

Knee osteoarthritis (KOA) is a prevalent and disabling condition worldwide, currently affecting over 32 million Americans and projected to impact 78 million by 2040. Existing treatment options primarily focus on symptom relief through pain management, intra-articular steroids, or surgery, as no disease-modifying therapies have been approved to date. The burden of KOA increases sharply with age, affecting approximately 30% of individuals by age 60, with about half of knee OA patients being 60 years or older. These demographics are expanding in line with global aging trends, highlighting the urgent need for durable therapeutic options.

Enlivex’s dual strategy combines the development of quality longevity therapeutics like Allocetra™ with a prediction markets treasury approach. The company operates a treasury strategy built around the Rain protocol, a leading decentralized prediction markets infrastructure on the Arbitrum blockchain, providing exposure to the emerging prediction markets ecosystem alongside its clinical programs.

The Australian patent issuance reinforces Enlivex’s commitment to protecting its innovative therapies across major jurisdictions as it advances clinical development. The company’s ongoing Phase 2b clinical program aims to establish Allocetra™ as a disease-modifying treatment for osteoarthritis, potentially addressing a significant unmet medical need in an aging population.

This announcement contains forward-looking statements subject to risks and uncertainties, including those related to clinical trial outcomes, regulatory approvals, market conditions, and the company’s digital asset treasury strategy. Actual results may differ materially from those expressed or implied. Enlivex undertakes no obligation to update these statements except as required by law.